Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11545
Title: Hypocalcemia induced by raloxifene.
Austin Authors: Vu, Thuy D T;Varadarajan, Suresh;Seeman, Ego ;Jerums, George ;MacIsaac, Richard J
Affiliation: Endocrinology Department, Austin Health, Victoria, Australia
Issue Date: 1-Apr-2012
Publication information: Current Drug Safety; 7(2): 176-8
Abstract: Raloxifene is an anti-resorptive agent used in postmenopausal osteoporosis. This is the first report of the occurrence of clinically significant hypocalcemia following raloxifene treatment in a patient with occult vitamin D deficiency. Since vitamin D deficiency is widely prevalent in the community, screening for vitamin D deficiency and its correction is advisable before the initiation of anti-resorptive therapy.
Gov't Doc #: 22873502
URI: http://ahro.austin.org.au/austinjspui/handle/1/11545
URL: https://pubmed.ncbi.nlm.nih.gov/22873502
Type: Journal Article
Subjects: Aged, 80 and over
Bone Density Conservation Agents.adverse effects.therapeutic use
Female
Humans
Hypocalcemia.chemically induced
Mass Screening.methods
Osteoporosis, Postmenopausal.drug therapy
Raloxifene.adverse effects.therapeutic use
Vitamin D Deficiency.complications.diagnosis
Appears in Collections:Journal articles

Show full item record

Page view(s)

12
checked on Dec 6, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.